{'fraction_non_alphanumeric': 0.02277163305139883, 'fraction_numerical': 0.01626545217957059, 'mean_word_length': 5.152, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
p53 Protein Expression in Chronic Myelomonocytic Leukemia-1 Correlates with Progression to Leukemia and a Poor Prognosis

CMML-1 is controversial. Herein, we performed a retrospective study of the clinical features of patients with CMML-1 in a single institution. In our institution, 20 patients with CMML-1 reclassified retrospectively based on the WHO (2008) criteria and diagnosed as having CMML based on the FAB or WHO (2001) classification were included in this study. Rearrangement of PDGFRA or PDGFRB was excluded in case of eosinophilia. Our series excluded cases of secondary CMML associated with therapy-related MDS/AML. Patients were followed up from 1996 to 2008. Mutational analysis was performed on DNA from BM cells from the study participants. All samples were obtained with informed consent, and the protocols were approved by our institution’s ethics committee. The clinical characteristics and laboratory data were determined by a review of medical records. Laboratory and physical examination data of all patients were obtained at diagnosis. BM aspiration and biopsy samples were taken and analyzed at diagnosis and at the time of transformation to AML. Chromosomal analyses of BM cells were performed by G-banding techniques. Hydroxyurea was used as a cytoreductive drug in some of the CMML patients. After the Chronic myelomonocytic leukemia (CMML) is characterized by persistent monocytosis and by features of a myeloproliferative neoplasm and a myelodysplastic syndrome (MDS). CMML is subdivided into CMML-1, with